Agitation Associated With Alzheimer’s Dementia (AAD): A Focus On Stigma
In March 2023, we launched a survey of PsychU members to assess the stigma associated with AAD. This infographic summarizes the results of the survey. Over a 30-day period, 194 PsychU members shared their thoughts on stigma associated with AAD. 52% of respondents currently managed patients with AAD. Among respondents currently managing patients with AAD, 91% of respondents believed that there is stigma associated with AAD, 93% endorsed that stigma associated with AAD negatively impacts patient care, and 96% reported that the healthcare community needs more educational resources about stigma in AAD. In summary, our PsychU community identified a stigma associated with AAD that negatively impacts patient care, which is a new target for future PsychU content development. Thank you to our PsychU members who participated in the survey!
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.